- Home
- FLC vs BWAY Comparison
FLC vs BWAY Comparison
Compare FLC & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLC
- BWAY
- Stock Information
- Founded
- FLC 2003
- BWAY 2003
- Country
- FLC United States
- BWAY Israel
- Employees
- FLC N/A
- BWAY N/A
- Industry
- FLC Trusts Except Educational Religious and Charitable
- BWAY Medical/Dental Instruments
- Sector
- FLC Finance
- BWAY Health Care
- Exchange
- FLC Nasdaq
- BWAY Nasdaq
- Market Cap
- FLC 176.2M
- BWAY 177.4M
- IPO Year
- FLC N/A
- BWAY 2019
- Fundamental
- Price
- FLC $16.96
- BWAY $10.28
- Analyst Decision
- FLC
- BWAY Strong Buy
- Analyst Count
- FLC 0
- BWAY 3
- Target Price
- FLC N/A
- BWAY $13.17
- AVG Volume (30 Days)
- FLC 37.8K
- BWAY 57.5K
- Earning Date
- FLC 01-01-0001
- BWAY 03-05-2025
- Dividend Yield
- FLC 6.64%
- BWAY N/A
- EPS Growth
- FLC N/A
- BWAY N/A
- EPS
- FLC N/A
- BWAY 0.04
- Revenue
- FLC N/A
- BWAY $38,631,000.00
- Revenue This Year
- FLC N/A
- BWAY $388.82
- Revenue Next Year
- FLC N/A
- BWAY $18.70
- P/E Ratio
- FLC N/A
- BWAY $128.37
- Revenue Growth
- FLC N/A
- BWAY 34.19
- 52 Week Low
- FLC $12.62
- BWAY $4.61
- 52 Week High
- FLC $15.45
- BWAY $11.25
- Technical
- Relative Strength Index (RSI)
- FLC 55.02
- BWAY 46.35
- Support Level
- FLC $16.80
- BWAY $10.24
- Resistance Level
- FLC $17.08
- BWAY $10.89
- Average True Range (ATR)
- FLC 0.21
- BWAY 0.47
- MACD
- FLC 0.00
- BWAY -0.04
- Stochastic Oscillator
- FLC 69.49
- BWAY 10.34
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.